The integration of deep learning (DL) with multi-omics data has significantly advanced our understanding of biological systems, particularly in cancer research. DL enables the analysis of high-dimensional datasets and the discovery of novel disease mechanisms and biomarkers, contributing to improved patient treatment and management. This review provides a detailed overview of recent developments in deep learning models applied to genomics data, with a focus on cancer type classification, driver gene identification, survival analysis, and drug response prediction. We introduce the foundational concepts of machine and deep learning and explain the characteristics of multi-omics data, addressing a broad and interdisciplinary audience. Methods published since 2020 are systematically reviewed, including their model architectures, datasets, and key innovations.

Survival analysis often relies on Cox models, assuming both linearity and proportional hazards (PH). This study evaluates machine and deep learning methods that relax these constraints, comparing their performance with penalized Cox models on a benchmark of three synthetic and three real datasets. In total, eight different models were tested, including six non-linear models of which four were also non-PH. Although Cox regression often yielded satisfactory performance, we showed the conditions under which machine and deep learning models can perform better. Indeed, the performance of these methods has often been underestimated due to the improper use of Harrell's concordance index (C-index) instead of more appropriate scores such as Antolini's concordance index, which generalizes C-index in cases where the PH assumption does not hold. In addition, since occasionally high C-index models happen to be badly calibrated, combining Antolini's C-index with Brier's score is useful to assess the overall performance of a survival method. Results on our benchmark data showed that survival prediction should be approached by testing different methods to select the most appropriate one according to sample size, non-linearity and non-PH conditions. To allow an easy reproducibility of these tests on our benchmark data, code and documentation are freely available at https://github.com/compbiomed-unito/survhive.

Several computational pipelines for biomedical data have been proposed to stratify patients and to predict their prognosis through survival analysis. However, these analyses are usually performed independently, without integrating the information derived from each of them. Clustering of survival data is an underexplored problem, and current approaches are limited for biomedical applications, whose data are usually heterogeneous and multimodal, with poor scalability for high-dimensionality. We introduce VAE-Surv, a multimodal computational framework for patients' stratification and prognosis prediction. VAE-Surv integrates a Variational Autoencoder (VAE), which reduces the high-dimensional space characterizing the molecular data, with a deep survival model, which combines the embedded information with the clinical features. The VAE embedding step prioritizes local coherence within the feature space to detect potential nonlinear relationships among the molecular markers. The latent representation is then exploited to perform K-means clustering. To test the clinical robustness of the algorithm, VAE-Surv was applied to the Genomed4all cohort of Myelodysplastic Syndromes (MDS), comparing the identified subtypes with the World Health Organization (WHO) classification. The survival outcome was compared with the state-of-the-art Cox model and its penalized versions. Finally, to assess the generalizability of the results, the method was also validated on an external MDS cohort. Tested on 2,043 patients in the GenomMed4All cohort, VAE-Surv achieved a median C-index of 0.78, outperforming classical approaches. In addition, the latent space enhanced the clustering performance compared to a traditional approach that applies the clustering directly to the input data. Compared to the WHO 2016 MDS subtypes, the analysis of the identified clusters showed that the proposed framework can capture existing clinical categorizations while also suggesting novel, data-driven patient groups. Even tested in an external MDS cohort of 2,384 patients, VAE-Surv achieved a good prediction performance (median C-index=0.74), preserving the interpretability of the main clinical and genetic features. VAE-Surv enables automatic identification of patients' clusters, while outperforming the traditional CoxPH model in survival prediction tasks at the same time. Applied to MDS use case, the obtained genetic-based clusters exhibit a clear survival stratification, and the application of the clinical information allowed high performance in prognosis prediction.

Myositis ossificans is a pseudoinflammatory tumour that originates from skeletal muscle and corresponds to a heterotopic, metaplastic, nonmalignant bone tumour. The purpose of this article is to report the case of myositis ossificans circumscripta (MOC) of the psoas muscle due to overuse in an adolescent gymnast. A 16-year-old female athlete presented at our outpatient orthopaedic clinic for evaluation of a 1-month history of low back pain. Initial plain radiographs were initially interpreted as negative, and laboratory values were normal. MRI imaging demonstrated a circumscribed mass with associated oedema in the psoas muscle. Computed tomography-guided percutaneous biopsy was performed and histology confirmed the diagnosis of MOC. Conservative treatment was initiated with rest and anti-inflammatory drugs (indomethacin). The patient had a resolution of pain and function after 3 months of conservative treatment. At 6 months' follow-up, MRI demonstrated complete resolution of the lesion and she gradually returned to her sports activity. At last follow-up she was asymptomatic. MOC is a rare lesion in the paediatric-adolescent population. To our knowledge, this is the first report of MOC in the psoas muscle produced by overuse. MRI is very sensitive in detecting oedema during the acute phase of the lesion. Conservative treatment should be considered, especially at the early stage of the disease. Spontaneous resolution can be expected in most cases.

Survival analysis, a foundational tool for modeling time-to-event data, has seen growing integration with machine learning (ML) approaches to handle the complexities of censored data and time-varying risks. Despite these advances, leveraging state-of-the-art survival models remains a challenge due to the fragmented nature of existing implementations, which lack standardized interfaces and require extensive preprocessing. We introduce SurvHive, a Python-based framework designed to unify survival analysis methods within a coherent and extensible interface modeled on scikit-learn. SurvHive integrates classical statistical models with cutting-edge deep learning approaches, including transformer-based architectures and parametric survival models. Using a consistent API, SurvHive simplifies model training, evaluation, and optimization, significantly reducing the barrier to entry for ML practitioners exploring survival analysis. The package includes enhanced support for hyper-parameter tuning, time-dependent risk evaluation metrics, and cross-validation strategies tailored to censored data. With its extensibility and focus on usability, SurvHive provides a bridge between survival analysis and the broader ML community, facilitating advancements in time-to-event modeling across domains. The SurvHive code and documentation are available freely at https://github.com/compbiomed-unito/survhive.